Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.

Détails

ID Serval
serval:BIB_471CEC1954C0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.
Périodique
Frontiers in oncology
Auteur(s)
Oehl K., Kresoja-Rakic J., Opitz I., Vrugt B., Weder W., Stahel R., Wild P., Felley-Bosco E.
ISSN
2234-943X (Print)
ISSN-L
2234-943X
Statut éditorial
Publié
Date de publication
2018
Peer-reviewed
Oui
Volume
8
Pages
40
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Experimental models closely representing <i>in vivo</i> conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can be obtained <i>in vitro</i> , providing a useful tool to investigate underlying mechanisms. Primary mesothelioma cultures were established from 235 samples between 2007 and 2014. Of two MPM patients, primary cultures obtained at different time points: at initial diagnosis, after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply investigated. Cells and corresponding tumor tissue were characterized by mesothelial protein and gene expression analysis. In addition, primary cultures from chemo naive patients were exposed to increasing doses of cisplatin/pemetrexed during three months and compared with non-treated cells in a cytotoxicity assay, and by selected profiling of senescence markers. <i>In vitro</i> chemoresistance in the primary mesothelioma cell cultures was associated with increased Thy1 (CD90) expression. Thy1 expression in MPM samples was significantly associated with poor overall survival in the TCGA MPM cohort. Our results illustrate that the establishment of a large live-cell MPM biobank contributes to a better understanding of therapy resistance observed <i>in vivo</i> , which eventually may lead to a more logical approach for developing new treatment strategies.
Mots-clé
chemoresistance, cisplatin and pemetrexed, copy number, genetic profiling, mesothelioma, mutations, primary culture, tumor progression
Pubmed
Web of science
Open Access
Oui
Création de la notice
20/08/2018 15:46
Dernière modification de la notice
08/05/2019 17:59
Données d'usage